Strategies in the design of nanoparticles for therapeutic applications

被引：2882

作者：

Petros, Robby A. ^{[1
]}

DeSimone, Joseph M. ^{[2
,3
,4
,5
]}

机构：

[1] Univ N Texas, Dept Chem, Denton, TX 76203 USA

[2] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA

[3] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA

[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[5] N Carolina State Univ, Dept Chem Engn, Raleigh, NC 27695 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 08期

基金：

美国国家科学基金会;

关键词：

DRUG-DELIVERY SYSTEMS; B-CELL LYMPHOMA; PHASE-I; TARGETED DELIVERY; INTRACELLULAR TRAFFICKING; CHEMOTHERAPEUTIC-AGENTS; COMPLEMENT ACTIVATION; ALBUMIN MICROSPHERES; CANCER-CHEMOTHERAPY; CONTROLLED-RELEASE;

D O I：

10.1038/nrd2591

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Engineered nanoparticles have the potential to revolutionize the diagnosis and treatment of many diseases; for example, by allowing the targeted delivery of a drug to particular subsets of cells. However, so far, such nanoparticles have not proved capable of surmounting all of the biological barriers required to achieve this goal. Nevertheless, advances in nanoparticle engineering, as well as advances in understanding the importance of nanoparticle characteristics such as size, shape and surface properties for biological interactions, are creating new opportunities for the development of nanoparticles for therapeutic applications. This Review focuses on recent progress important for the rational design of such nanoparticles and discusses the challenges to realizing the potential of nanoparticles.

引用

页码：615 / 627

页数：13

共 173 条

[71] PEGylation of nanocarrier drug delivery systems: State of the art [J].